Literature DB >> 22118966

Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.

Josef Wanninger1, Sabrina Bauer, Kristina Eisinger, Thomas S Weiss, Roland Walter, Claus Hellerbrand, Andreas Schäffler, Akiko Higuchi, Kenneth Walsh, Christa Buechler.   

Abstract

Chemokine-like receptor 1 (CMKLR1) ligands chemerin and resolvin E1 are suggested to have a role in non-alcoholic fatty liver disease (NAFLD). Here, expression of CMKLR1 in liver cells and NAFLD was studied. CMKLR1 was detected in primary human hepatocytes (PHH), Kupffer cells, bile-duct cells and hepatic stellate cells. In human and rodent fatty liver and in fibrotic liver of mice fed a methionine-choline deficient diet CMKLR1 was reduced. Hepatocytes are the major cells in the liver and effects of adipokines, cytokines and lipids on CMKLR1 in PHH were analyzed. Increased cellular triglyceride or cholesterol content, lipopolysaccharide, IL-6, TNF and leptin did not influence CMKLR1 levels in PHH whereas profibrotic TGFβ tended to reduce CMKLR1. Adiponectin strongly upregulated CMKLR1 mRNA and protein in PHH and hepatic CMKLR1 when injected into wild type mice. Further, CMKLR1 was suppressed in the liver of adiponectin deficient mice. These data indicate that low CMKLR1 in NAFLD may partly result from reduced adiponectin activity.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118966      PMCID: PMC3670424          DOI: 10.1016/j.mce.2011.10.032

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  57 in total

1.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

Review 2.  Chemerin: at the crossroads of inflammation and obesity.

Authors:  Matthew C Ernst; Christopher J Sinal
Journal:  Trends Endocrinol Metab       Date:  2010-11       Impact factor: 12.015

3.  Chemerin, a novel adipokine in the regulation of angiogenesis.

Authors:  Kiymet Bozaoglu; Joanne E Curran; Claire J Stocker; Mohamed S Zaibi; David Segal; Nicky Konstantopoulos; Shona Morrison; Melanie Carless; Thomas D Dyer; Shelley A Cole; Harald H H Goring; Eric K Moses; Ken Walder; Michael A Cawthorne; John Blangero; Jeremy B M Jowett
Journal:  J Clin Endocrinol Metab       Date:  2010-03-17       Impact factor: 5.958

4.  MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis.

Authors:  Josef Wanninger; Roland Walter; Sabrina Bauer; Kristina Eisinger; Andreas Schäffler; Christoph Dorn; Thomas S Weiss; Claus Hellerbrand; Christa Buechler
Journal:  Exp Mol Pathol       Date:  2011-07-21       Impact factor: 3.362

Review 5.  Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.

Authors:  Andreas Schäffler; Jürgen Schölmerich; Christa Büchler
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2005-06

6.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

Review 7.  Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1.

Authors:  Hiroyuki Seki; Yukako Tani; Makoto Arita
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-25       Impact factor: 3.072

8.  Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157).

Authors:  Vivian Berg; Baldur Sveinbjörnsson; Signy Bendiksen; Jan Brox; Khaled Meknas; Yngve Figenschau
Journal:  Arthritis Res Ther       Date:  2010-12-30       Impact factor: 5.156

9.  Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids.

Authors:  Valérie Wittamer; Jean-Denis Franssen; Marisa Vulcano; Jean-François Mirjolet; Emmanuel Le Poul; Isabelle Migeotte; Stéphane Brézillon; Richard Tyldesley; Cédric Blanpain; Michel Detheux; Alberto Mantovani; Silvano Sozzani; Gilbert Vassart; Marc Parmentier; David Communi
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

10.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23.

Authors:  Jenna L Cash; Rosie Hart; Andreas Russ; John P C Dixon; William H Colledge; Joanne Doran; Alan G Hendrick; Mark B L Carlton; David R Greaves
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  19 in total

1.  Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation.

Authors:  Y Lin; X Yang; W Liu; B Li; W Yin; Y Shi; R He
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

2.  Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.

Authors:  Kerstin Abshagen; Alexander Hartmann; Laura Grüner; Marie Liebig; Brigitte Vollmar
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

Review 3.  Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.

Authors:  Corneliu Sima; Ana Viniegra; Michael Glogauer
Journal:  J Leukoc Biol       Date:  2018-11-19       Impact factor: 4.962

4.  Resolution of inflammation in obesity-induced liver disease.

Authors:  Bibiana Rius; Cristina López-Vicario; Ana González-Périz; Eva Morán-Salvador; Verónica García-Alonso; Joan Clária; Esther Titos
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

5.  Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.

Authors:  Nanda Gruben; Marcela Aparicio Vergara; Niels J Kloosterhuis; Henk van der Molen; Stefan Stoelwinder; Sameh Youssef; Alain de Bruin; Dianne J Delsing; Jan Albert Kuivenhoven; Bart van de Sluis; Marten H Hofker; Debby P Y Koonen
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

6.  Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C.

Authors:  Michał Kukla; Brygida Adamek; Marek Waluga; Marzena Zalewska-Ziob; Janusz Kasperczyk; Andrzej Gabriel; Włodzimierz Mazur; Barbara Sobala-Szczygieł; Rafał J Bułdak; Wojciech Zajęcki; Lucjan Kępa; Katarzyna Ziora; Krystyna Żwirska-Korczala; Andrzej Wiczkowski; Marek Hartleb
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

Review 7.  International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function.

Authors:  Amanda J Kennedy; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2017-12-26       Impact factor: 25.468

Review 8.  Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes.

Authors:  Corneliu Sima; Bruce Paster; Thomas E Van Dyke
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

9.  Lactoferrin dampens high-fructose corn syrup-induced hepatic manifestations of the metabolic syndrome in a murine model.

Authors:  Yi-Chieh Li; Chang-Chi Hsieh
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

10.  Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals.

Authors:  Maximilian Neumann; Elisabeth M Meier; Lisa Rein-Fischboeck; Sabrina Krautbauer; Kristina Eisinger; Charalampos Aslanidis; Rebekka Pohl; Thomas S Weiss; Christa Buechler
Journal:  Int J Mol Sci       Date:  2016-08-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.